![]() We felt like we were kicking the can down the road," says Stahlecker. "Before CAR-T, we knew every treatment was temporary and just hoped it would keep me in remission long enough for something new to be made available. "We hope through research more patients will experience healing and we'll increase the long-term remission rate, make the therapy safer and extend its application to other cancers." "It shows us there is room for improvement," says Dr. Six died waiting for infusion, and 43 others died after receiving CAR-T cell therapy for CLL. One-third of the patients in the trial did not respond at all. The multi-site, industry-sponsored trial enrolled 117 patients with CLL and small lymphocytic lymphoma. CAR-T cell therapy has Food and Drug Administration approval for some B-cell lymphomas and leukemias and multiple myeloma, but not for CLL. In advanced disease, treatment options are limited and many patients have poor outcomes.ĬAR-T cell therapy is regenerative immunotherapy aimed at harnessing the power of genetically modified T-cells to kill cancer. In patients with CLL who achieve deep, complete remissions, so far we are not seeing relapses even years later, " says Saad Kenderian, M.B, Ch.B., principal investigator and hematologist at Mayo Clinic.Ĭhronic lymphocytic leukemia is a common cancer in which the bone marrow makes too many white blood cells. "Overall, I am encouraged by the findings. The research found that 18% of participants with relapsing CLL who no longer responded to standard treatments such as chemotherapy or BTK inhibitor drugs experienced complete remission after a single infusion of standard CAR-T cell therapy. Stahlecker's results are part of a CAR-T cell therapy study documented in The Lancet. He's remained cancer-free for three-and-a-half years. Sixty days later, a bone marrow biopsy found no trace of cancer. A baseline bone marrow test done before his infusion showed 80% of his cells were cancerous. ![]() Recognizing CAR-T cell therapy as his last option, the Wausau, Wisconsin, native enrolled in the trial in the fall of 2019. When you think you may only have a couple years left, it's very difficult to make plans for the future." "We had bought land to build a house but put that on hold. ![]() I was trying to see as many people and relatives as I could," says Stahlecker. Jon Stahlecker had exhausted all treatment options and lost hope of surviving chronic lymphocytic leukemia (CLL) before Mayo Clinic offered him chimeric antigen receptor-T cell therapy (CAR-T cell therapy) in a clinical trial. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |